AZD2171

Drugs in the pipeline: new therapies that could change treatment strategies

...n cancers and lymphoma. A Multidisciplinary Phase II Study of azd2171 (cediranib), an Oral Pan-VEGF Receptor Tyrosine Kinase Inhibitor, in Patien...s with Recurrent Glioblastoma: Abstract LB-247 The investigational drug azd2171 (cediranib) may help shrink tumors and prolong survival of patients with a ...

Scientists Developing New Drug To Treat Bowel Cancer

... Experimental studies on mice with a drug called azd2171 which reduced the size and number of polyps in mice have led to the hope // that it could someday soon be used in humans with bowel cancer. The...

AZD2171 in other areas

Cediranib - Wikipedia, the free encyclopedia

Cediranib, also known as AZD2171, is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases.

HemOnc Today Mobile - Home

AZD2171, an oral pan-VEGF receptor tyrosine kinase inhibitor, was a safe and ... The early experience with AZD2171 suggests that this is a manageable drug, ...

Study to Investigate the Management of Hypertension and Efficacy of ...

Drug: AZD2171. Phase II. Study Type: Interventional. Study Design: ... To estimate the activity of AZD2171 monotherapy using objective response rate ...

AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That ...

RATIONALE: AZD2171 may stop the growth of tumor cells by blocking some of the ... Patients receive oral AZD2171 once daily on days 1-28. Courses repeat every 28 ...

AZD2171 Shows Potent Antitumor Activity Against Gastric Cancer Over ...

AZD2171 completely inhibited the phosphorylation of FGFR2 and downstream ... Oral administration of AZD2171 (1.5 or 6 mg/kg/d) significantly and dose ...

Page 1 of 4 Protocol Abstract and Schema

A pediatric phase I trial AZD2171 will be performed in children and adolescents ... evidence of biologic activity of AZD2171 by evaluating alterations in ...